VCANBIO CELL & GENE ENGINEERING CORP., LTD Vcanbio Cell & Gene Engineering Corp., Ltd Stock
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.45 CNY | +0.73% |
|
+6.68% | -18.85% |
| Sales 2022 | 1.55B 215M | Sales 2023 | 1.59B 219M | Capitalization | 9.49B 1.31B |
|---|---|---|---|---|---|
| Net income 2022 | 113M 15.6M | Net income 2023 | 106M 14.63M | EV / Sales 2022 | 4.31 x |
| Net cash position 2022 | 1.25B 173M | Net cash position 2023 | 1.47B 202M | EV / Sales 2023 | 5.04 x |
| P/E ratio 2022 |
70.9
x | P/E ratio 2023 |
88.1
x | Employees | 2,332 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.64% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.73% | ||
| 1 week | +6.68% | ||
| Current month | +0.30% | ||
| 1 month | +0.73% | ||
| 3 months | -5.24% | ||
| 6 months | -10.55% | ||
| Current year | -18.85% |
1 week
15.22
16.50
1 month
15.0516.65
Current year
12.8820.35
1 year
12.8821.77
3 years
12.8828.67
5 years
12.8834.77
10 years
12.8879.58
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Wang
CEO | Chief Executive Officer | 57 | 09-06-29 |
Xiao Ting Wang
DFI | Director of Finance/CFO | 42 | 22-05-24 |
Hai Bin Li
BRD | Director/Board Member | 53 | 16-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Wang
CEO | Chief Executive Officer | 57 | 09-06-29 |
Xin Yi Hou
BRD | Director/Board Member | 64 | 20-05-18 |
Hong Qi Wang
BRD | Director/Board Member | 59 | 23-05-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 16.45 | +0.73% | 4,613,369 |
| 24-04-25 | 16.33 | +1.24% | 4,311,099 |
| 24-04-24 | 16.13 | +1.38% | 3,420,213 |
| 24-04-23 | 15.91 | +1.73% | 3,544,628 |
| 24-04-22 | 15.64 | +1.43% | 4,008,999 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.85% | 1.06B | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| +1.78% | 5.41B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.29B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B |
- Stock Market
- Equities
- 600645 Stock
